DTM Overview

Analyst Recommendation: B of A Securities has maintained a Buy recommendation for DT Midstream (NYSE:DTM) as of December 11, 2025, with an average one-year price target of $120.17/share, indicating a potential upside of 0.49%.

Revenue and Earnings Projections: DT Midstream's projected annual revenue is $1,049 million, reflecting a decrease of 10.72%, while the projected annual non-GAAP EPS is 4.70.

Fund Sentiment: There are 1,096 funds reporting positions in DT Midstream, with a slight decrease of 2.66% in ownership over the last quarter, and an average portfolio weight of 0.35%, which has increased by 3.70%.

Shareholder Activity: Notable shareholders like IJH and VTSMX have increased their holdings in DT Midstream, while others like Deutsche Bank and Goldman Sachs have significantly reduced their portfolio allocations in the last quarter.

Upcoming Ex-Dividend Dates: On 12/15/25, DT Midstream Inc (DTM), HCA Healthcare Inc (HCA), and Thermo Fisher Scientific Inc (TMO) will trade ex-dividend, with respective dividends of $0.82, $0.72, and $0.43 scheduled for payment on 1/15/26 and 12/29/25.

Expected Price Adjustments: Following the ex-dividend date, shares of DTM are expected to open 0.70% lower, HCA by 0.15% lower, and TMO by 0.07% lower, based on their recent stock prices.

Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 2.79% for DT Midstream Inc, 0.61% for HCA Healthcare Inc, and 0.30% for Thermo Fisher Scientific Inc, reflecting their historical dividend stability.

Current Trading Performance: As of Thursday trading, DT Midstream Inc shares are down about 1.3%, HCA Healthcare Inc shares are down about 4%, while Thermo Fisher Scientific Inc shares have increased by about 1.9%.

Analyst Ratings Overview: Recent ratings for DT Midstream show a mix of bullish and bearish sentiments, with 4 bullish, 3 indifferent, and 1 somewhat bearish rating among 8 analysts over the past three months.

Price Target Insights: Analysts have set an average 12-month price target of $120.25 for DT Midstream, reflecting a 7.37% increase from the previous average of $112.00, with estimates ranging from $108.00 to $130.00.

Financial Performance Highlights: DT Midstream has demonstrated strong revenue growth of approximately 26.61% and a net margin of 36.62%, although its return on equity (2.45%) and return on assets (1.15%) are below industry benchmarks.

Debt Management Strategy: The company maintains a prudent financial strategy with a below-average debt-to-equity ratio of 0.72, indicating a balanced approach to managing its debt levels.

Citigroup's Recommendation: Citigroup has maintained a Buy recommendation for DT Midstream (NYSE:DTM) as of October 9, 2025, with an average one-year price target of $111.35/share, indicating a slight upside of 0.16% from its latest closing price.

Fund Sentiment and Ownership Changes: There are 1,120 funds reporting positions in DT Midstream, with a slight decrease in the number of owners but an increase in total shares owned by institutions by 4.25% over the last three months. Notable increases in ownership were reported by Blackstone Group, iShares Core S&P Mid-Cap ETF, and Vanguard Total Stock Market Index Fund.